The clinical features of dementia with Lewy bodies (DLB) during wakefulness are well known. Other than rapid eye movement (REM) sleep behavior disorder, only limited data exists on other sleep disturbances and disorders in DLB. We sought to characterize the polysomnographic (PSG) findings in a series of DLB patients with sleep-related complaints.
D ementia with Lewy bodies (DLB) refers to the constellation of features that are typically associated with limbic or neocortical Lewy body disease. 1 DLB is now considered the second most common cause of neurodegenerative dementia after Alzheimer disease. 2 The revised consensus criteria 1 for the clinical diagnosis of DLB requires the presence of dementia plus the following core features: fluctuations in cognition or arousal, recurrent and fully formed visual hallucinations, and spontaneous parkinsonism. Two of these features are required for the diagnosis of probable DLB, and 1 for the diagnosis of possible DLB. A diagnosis of probable DLB may also be made with the presence of 1 core feature and one of the following suggestive features: rapid eye movement (REM) sleep behavior disorder (RBD), severe neuroleptic sensitivity or low dopamine transporter uptake in the basal ganglia on functional imaging. The importance of the diagnosis is underscored by the often positive response to cholinesterase inhibitors and the exquisite sensitivity often demonstrated with anticholinergics and neuroleptics with D2 antagonism. 1 RBD is a parasomnia in which patients seem to "act out their dreams." Ample data now suggest RBD occurs frequently in the synucleinopathies [eg, DLB, Parkinson disease (PD) with and without dementia, and multiple system atrophy] and rarely in the tauopathies. 3, 4 Some have argued that RBD should be considered a core feature of the disorder. 5 recent data have also shown that among those who have mild cognitive impairment associated with RBD who are followed longitudinally, almost all subsequently develop the other core features of DLB and all have underlying Lewy body disease found at autopsy. 7 Hence, RBD is clearly frequent in DLB and usually precedes the onset of the other core features of the disorder by many years.
There is little data on other common sleep disorders in those with DLB, such as upper airway resistance syndrome (UARS), obstructive sleep apnea/hypopnea syndrome (OSAHS), central sleep apnea syndrome (CSAS), and periodic limb movements (PLMs) of sleep. Furthermore, to what degree these and other disorders cause sleep fragmentation, reduced sleep efficiency, insomnia, or hypersomnia in DLB patients is not known. These sleep disorders are relatively common in the neurologically normal elderly, and untreated sleep disorders clearly can affect cognition, mood, daily functional status, and quality of life. The majority of sleep disorders are treatable, and hence appropriate therapy could improve nocturnal sleep continuity, reduce daytime hypersomnolence, and improve daytime functioning and quality of life for DLB patients and their bed partners/caregivers. Sleep disturbances are a major contributor to caregiver decision making in institutionalizing their loved ones who have dementia, which underscores the importance of recognizing, diagnosing, and treating the multitude of sleep disorders in this patient population. No systematic study has ever attempted to address the frequency of sleep disturbances in DLB.
In this study, we sought to characterize the polysomnographic (PSG) findings in a series of DLB patients who presented with sleep-related complaints to study the scope and relative frequency of sleep disturbances in this population.
DESIGN/METHODS

Case Ascertainment
We identified all DLB patients evaluated by one or more of the authors who underwent sleep medicine consultations and PSG at Mayo Clinic, Rochester and Mayo Clinic, Jacksonville between January 1992 and October 2002.
Inclusion Criteria
All subjects met criteria for clinically possible or probable DLB. 1 All patients and/or bed partners had sleep-related complaints warranting clinical sleep evaluations and PSGs, which included one or more of the following features: recurrent dream enactment behavior, excessive nocturnal movements, disruptive snoring with observed apnea, excessive daytime somnolence, or insomnia.
Data Collection
PSG recording and scoring were performed according to established guidelines. 8 All PSG studies involved continuous video synchronized to standard PSG monitoring using the following montage: 2 electro-oculogram derivations, 3 electroencephalography (EEG) derivations (Fz-Cz, Cz-Oz, C4-A1), electrocardiogram, chin and at least 2 limb surface electromyograms, oronasal airflow, sonogram, oxyhemoglobin saturation, and chest and abdomen inductance plethysmography. Scoring of sleep stages followed standard guidelines, 9 and each PSG was reviewed by a sleep medicine clinician certified by the American Board of Sleep Medicine. As all PSGs were performed during the 1992 to 2002 period that preceded the updated 2007 guidelines for defining and measuring sleep-related events, 10 the definitions for sleep-related events that were being used over 1992 to 2002 time period 11 are the definitions used in this study. The finding of REM sleep without atonia (RSWA) was considered present if muscle tone during REM sleep was considered unequivocally abnormally increased by an American Board of Sleep Medicine-certified sleep clinician and if no epileptiform discharges were noted on the record. 8 An arousal was defined as an abrupt shift of EEG frequency including alpha, theta, or frequency higher than 16 Hz but not sleep spindles after at least 10 seconds of stable sleep, that lasted at least 3 seconds during any sleep stage but not long enough to be classified as awake. An arousal during REM sleep was scored only if it was accompanied by increased amplitude of submental electromyogram. A disordered breathing event was defined as an obstructive apnea, central apnea, mixed apnea, hyponea episode, or respiratory effort related arousal (RERA). The disordered breathing arousal index (DBAI) was defined as the average number of arousals per hour associated with a disordered breathing event. For an obstructive event, there was a 10 seconds or longer period with clear amplitude decrease in breathing from baseline associated with over 3% oxygen desaturation or an arousal from the obstructive events. In a central event, there was a reduction or absence of breathing and respiratory effort that lasted 10 seconds or longer, with associated reduced airflow and esophageal pressure. For a hypopnea, there was a reduction of airflow and reduction of thoracic and/or abnormal movement that lead to an arousal. RERA was considered present when a respiratory effort such as a snort was associated with an arousal. The respiratory disturbance index (RDI) represents the sum of disordered breathing events related to obstructive apneas, central apneas, mixed apneas, hypopneas, and respiratory effort-related changes averaged over the total sleep time, which represents a value of this sum per hour. A PLM was defined as periodic contraction of lower legs either unilateral or bilateral, with a series of 4 consecutive movements separated by 4 to 90 seconds, each movement lasted between 0.5 and 5 seconds, and was not associated with respiratory events. The mean number of PLMs per hour associated with arousals was considered the periodic limb movement arousal index (PLMAI). An arousals for no apparent reason (AFNAR) was defined as an arousal not related to disordered breathing or movements, and the arousals for no apparent reason index (AFNARI) represents the number of AFNARs per hour averaged over total sleep time. Sleep efficiency was defined as the total sleep time divided by the total time in bed multiplied by 100%.
We routinely perform split-night studies for those patients who have clinically significant sleep disordered breathing, meaning that those who have an RDI of 5 or more per hour are routinely initiated in continuous positive airway pressure (CPAP) after 3 or 4 hours of the study. For such patients, the initial hours of observational assessment of sleep is considered the diagnostic portion of the study, and the subsequent portion in which the patients are administered CPAP therapy is considered the therapeutic portion of the study. For patients who had full-night PSGs (ie, had no significant disordered breathing events and therefore CPAP therapy was not administered), data over the entire study were analyzed. For those patients who had split-night studies (ie, had significant disordered breathing such that CPAP therapy was initiated halfway through the night), only data from the initial diagnostic portion of the study when the patients were not on CPAP were analyzed.
For patients who underwent evaluations for hypersomnolence, all psychoactive medications were suggested to be discontinued for at least 2 weeks in preparation for a PSG/multiple sleep latency test (MSLT), and at least 7 hours of total sleep time was attempted on the PSG immediately before the MSLT. Medications that were preferentially discontinued included sedative/hypnotics, clonazepam, antidepressants, and psychostimulants. For ethical reasons, cholinesterase inhibitors tended to be maintained because of the rare but well-known phenomenon of marked clinical worsening with cholinesterase inhibitor withdrawal that does not reverse upon reinstitution of the drug. Donepezil was always administered once daily in the morning, and the second daily dose of rivastigmine or galantamine were administered no later than suppertime. Note that the extended release preparations of transdermal rivastigmine and extended release galantamine became available over more recent years, and were not yet available at during the observation period of this analysis (January 1992 to October 2002). Also for ethical reasons, if visual hallucinations, delusions, agitation, etc. were viewed too severe to justify discontinuation of atypical neuroleptics, which in our patient population involves quetiapine almost exclusively, this agent was maintained.
Data Analysis
The following variables were analyzed on the PSGs: presence of RSWA, RDI, PLMAI, AFNARI, total arousal index (TAI), and percent sleep efficiency. TAI is further subdivided into percentages from disordered breathing, movement, or no apparent reason. The diagnosis of UARS was made for patients who had 5 or more RERAs per hour. The diagnosis of OSAHS was made for patients who had 5 or more obstructive hypopneas or apneas with arousals per hour. The diagnosis of CSAS was made for patients who had 5 or more central hypopneas or apneas with arousals per hour. For those who underwent MSLT, the mean initial sleep latency (ISL) and number of sleep onset rapid eye movement periods (SOR-EMPs) were analyzed. Values on the mean ISL were viewed as follows: >10 minutes = normal, <5 minutes = severe hypersomnolence, 5 to 10 minutes = borderline hypersomnolence (additional clinical data are required to interpret the MSLT data and decide on therapy). The presence of 2 or more SOREMPs was considered compatible with the diagnosis of narcolepsy in the appropriate clinical setting.
Informed Consent and Institutional Review Board (IRB) Approval
All patients (or their proxies) provide written consent before undergoing PSGs ± MSLTs, and spouses/caregivers are routinely requested to spend the night in the room of the patient's sleep study to help orient the patient and provide comfort if disorientation and anxiety occur during the study. Most of the DLB subjects were enrolled in one of the aging and dementia studies at Mayo Clinic-the Neuropsychology of DLB Study (AG015866), the Mayo Alzheimer Disease Research Center (AG016574), or the Mayo Clinic Study on Aging (AG006786), which are Mayo Foundation IRBapproved protocols. This specific analysis was also reviewed and approved by the Mayo IRB.
RESULTS
Data on 78 patients (71 male, 7 female) were analyzed ( Table 1 ). The mean age was 71 ± 8 years. Severity of dementia ranged from mild to moderate (mean total Mattis Dementia Rating Scale Score = 115 ± 18). Recurrent dream enactment behavior during sleep was reported to occur in 75 (96%) of the DLB subjects, and 65 (83%) of them had RSWA during PSG and thus confirmed RBD in these patients. Thirteen (17%) of the subjects did not attain any REM sleep, and hence RSWA could not be assessed. One patient without a history of RBD had RSWA. OSAHS criteria were met in 43 (55%) subjects. Fourteen (18%) had central hypopneas or apneas present, and 1 met criteria for the diagnosis of CSAS.
The mean values on other PSG data were as follows: sleep efficiency < 80% was found in 72% of the sample. Half the sample (49%) had sleep efficiency < 70%, and 26% of the sample had sleep efficiency <60% (Table 1 ). Sleep efficiency did not show any statistically significant correlation with age, dementia severity, body mass index, or PLM in our study. Other mean ( ± SD) values were: RDI = 11.9 ± 15.8, PLMAI = 5.9 ± 8.5, AFNARI = 10.7 ± 12.0, and TAI = 26.6 ± 17.4. Fortyseven patients (60%) patients had DBAIZ5, 35 (45%) patients had PLMAIZ5, 59 (76%) had AFNARIZ5, and all 78 (100%) had TAIZ5.
Twenty-three patients who had no evidence of clinically significant disordered breathing (RDI < 5) underwent full-night studies ( Table 2) ; sleep efficiency was 72.3% (SD 13.6). The TAI was 16.6 (SD 8.3), in which 61.9% (SD 22.3) was attributed to AFNAR, with 83% having an AFNARIZ5 (Tables 3 and 4 ). The remaining 55 patients with presence of disordered breathing, the TAI was 30.9 (SD 18.6), and 44.5% (SD 26.4) was due to breathing disorder, whereas 26.0% (SD 20.7) from AFNAR (Table 4) .
Six patients underwent evaluations with PSG plus MSLT. Two patients had mean ISLs on the MSLT <5 minutes, and both had DBAI < 5. No patient had any SOREMPs. Both with abnormal MSLT findings were diagnosed with a form of "idiopathic hypersomnia," which in hindsight may be better viewed as hypersomnia associated with an underlying neurodegenerative disorder, and both were treated with psychostimulants and benefited from such treatment.
Nineteen of these subjects have died and undergone neuropathologic examination ( Table 5 )-4 had limbic-predominant and 14 had neocortical-predominant Lewy body pathology, 1 whereas 1 with progressive supranuclear palsy (PSP). The patient with PSP had no REM sleep recorded on PSG, though a history of RBD was suspected. RSWA was detected in all but 4 neocortical-predominant Lewy body (LB) pathology patients. One (with neocortical-predominant type) out of these 19 patients was evaluated with MSLT, with a mean ISL being <5 minutes, and no SOREM recorded. The limbic-predominant and neocorticalpredominant LB pathology patients had similar sleep efficiency and AFNAR profile, but the neocortical-predominant LB pathology patients showed a higher trend in RDI and PLMAI than the limbic-predominant LB pathology patients. The PSP patient had a much better sleep efficiency in the study, and relatively lower AFNARI, and minimal PLMAI.
DISCUSSION
In this large cohort of patients with DLB and sleeprelated complaints, several sleep disturbances in addition to RBD were frequently present. To summarize, most had historical and electrophysiological evidence of RBD, most had reduced sleep efficiency, most had some degree of sleep-disordered breathing, most had some degree of PLMs during sleep, most had some degree of AFNAR, and a minority has historical and electrophysiological evidence of excessive daytime somnolence, although findings consistent with narcolepsy were absent in this cohort.
In 70% of the patients, sleep efficiency was below 80%, with arousals attributable to disordered breathing, PLMs during sleep, and spontaneous arousals. Sleep efficiency was not associated with age, dementia severity, or body mass index. Despite the findings that 60% of the sample had an RDIZ5, only 36% of the sample had an RDIZ10, indicating that moderate or severe sleep apnea does not entirely account for the poor sleep efficiency. Thus, when sleep apnea is present in this cohort, it tends to be mild and may contribute to poor sleep efficiency, but may not be solely responsible for it. When the sample includes only those with an RDI < 5, spontaneous arousals seem to be a predominant source of sleep disruption (83%), and PLMs are present in less than half (43%). Arousals that are not accounted for by breathing or movement disturbance are common, though a subset of patients do experience movement-related arousals associated with PLMs. RSWA, the electrophysiological substrate of RBD, was present in the vast majority of patients (96%), but did not solely account for poor sleep efficiency.
Sleep clinicians routinely search for historical clues and examination findings that make one suspicious for disordered breathing (loud disruptive snoring, observed snorts, gasps, and apneic pauses while sleeping, obesity, large collar size, crowded oropharynx); and for features suspicious of PLMs fragmenting sleep (such as restless legs syndrome or leg jerks as reported by the patient or bedpartner, history of gastrointestinal blood loss or anemia, clinical evidence of a peripheral neuropathy or radiculopathy). Yet despite comprehensive sleep histories and general and neurological examinations, we continue to be struck by the paucity of clues for disordered breathing and PLMs that can be elicited during the interview and examination, whereas so many of these DLB patients have the primary issues of daytime hypersomnia, insomnia, or dream enactment behavior warranting PSG. Our findings presented herein and continued clinical experience in evaluating and following patients with DLB have indicated that almost every DLB patient has one or more potentially treatable sleep disorders, even in the absence of obvious historical features. We now have a low threshold for performing clinical PSGs in DLB subjects who exhibit features of daytime hypersomnia, nocturnal insomnia, dream enactment behavior, or some combination of these.
UARS, OSAHS, and PLMs during sleep were present in a proportion of these patients. About 3/4 of the sample, however, had a significant number of arousals not accounted for by a Table 2 ). In a study by Unruh et al 9 that evaluated 5407 community dwelling adults that participated in the Sleep Heart Health Study that had undergone unattended home polysomnograms, 1719 were 60 years or older. The sleep efficiency for males is 80.2% (SD 10.9) for 60 to 69 year olds; 78.4% (SD 10.4) for 70 to 79 year olds; and 73.6% (SD 12.3) for those 80 years or older. One would expect in our patient sample the sleep efficiency will be lower as the patients and/or caregivers all complained of some type of sleep disturbances. Sleep efficiency in our group was <70% in half of the subjects. Yet the high number of AFNAR, especially in the group that does not show evidence of breathing disorder (Tables 2 and 3) , indicates that primary sleep disorders such as UARS, OSA, and PLMs do not entirely account for the poor sleep efficiency in DLB. These findings underscore the need to better understand the pathophysiological mechanisms underlying AFNAR. Instability in the wakefulness/sleep flipflop switch could be one cause, and considering the sleep-wake problems in those with PD and recent evidence of hypocretin-1 dysfunction in PD 12,13 -another phenotype of underlying LBD-one could hypothesize that hypocretin-1 dysfunction contributed to some of the complex pathophysiology of sleep fragmentation, drowsiness, and cognitive fluctuations in DLB. The high degree of accuracy of the DLB syndrome predicting underlying LBD pathology (Table 5 ) underscores the biological significance of our findings.
Of the 19 subjects in the study that have died and undergone neuropathologic examination, 4 had limbic-predominant, and 14 had neocortical-predominant Lewy body pathology. The 2 groups have similar sleep efficiency and AFNARI, and a higher trend in RDI and PLMAI is noticed in the neocorticalpredominant patients. Though there was a history suggestive of RBD in our PSP patient, we were unable to confirm RBD as no REM sleep was recorded in PSG. Interestingly, our PSP patient had a much better sleep efficiency than the DLB patients, with minimal PLMAI, and lower AFNARI. It will be interesting to see if AFNARs are also frequent in other neurodegenerative dementia with daytime somnolence, or if it is more specific to patients with DLB. Given that our autopsied study patient number with PSG is limited, larger groups of patients and with different dementia subtypes will be needed to verify our findings.
We acknowledge the limitations in this study. Our findings should not be interpreted as reflecting the actual prevalence of sleep disturbances and disorders in DLB, as our patients underwent PSGs for clinical purposes and are hence biased toward more sleep morbidity. It also should not be considered as the full scope of sleep disorders in DLB, as only 6 patients underwent MSLTs, and more might have met criteria for the diagnosis of narcolepsy or idiopathic hypersomnia had they undergone full PSG/MSLT evaluations. Performing and scoring PSGs in those with DLB are challenging-some refuse to undergo PSG for a variety of reasons, some become combative/uncooperative during the PSG that necessitates early discontinuation of the study, many have slowing on their background EEG and some have features of status dissociatus that makes scoring the PSG itself quite difficult.
Yet these findings suggest that further prospective studies are warranted to better understand the relationship between sleep disturbances, cognition, arousal, fluctuations, and DLB. Furthermore, successful diagnosis and treatment of sleep disorders may promote daytime functioning and quality of life for patients and their caregivers, and delay the need for institutionalization. Even purely from the financial perspective, the expenses associated with a sleep medicine consultation, polysomnogram, medication(s), or CPAP would equate to 1 to 2 months worth of skilled nursing care expenses, suggesting that a delay in nursing home placement from successful treatment of one or more sleep disorders could reduce health care costs for some families by thousands or tens of thousands of dollars. Health care expenditures associated with successful treatment of sleep disorders in DLB patients (and dementia patients in general) is certainly worthy of future research as well. 
